At PhalconBio, we are addressing the urgent issue of antibiotic resistance by developing next-generation antibacterial therapies. Our cutting-edge phage therapy platform enhances treatment effectiveness, reduces drug resistance, and provides highly targeted solutions.
Our primary focus is on treating pulmonary Pseudomonas aeruginosa infections, which are associated with chronic lung conditions as well as hospital-acquired pneumonia. Our adaptable platform allows us to expand our solutions to other critical ESKAPEE pathogens, setting a new standard in precision antibacterial treatments.
Company Details
- Employees
- 4
- Address
- Wädenswil, Zürich 8820, Ch
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.phalconbio.com
- Keywords
- Antibiotic Resistance, Biotechnology, R&D, Pharma, AMR, Phage Therapy, Infectious Diseases.
- HQ
- Wädenswil, Zürich
Phalconbio Questions
Phalconbio's website is http://www.phalconbio.com
Phalconbio's LinkedIn profile is https://ch.linkedin.com/company/phalconbio
Phalconbio has
4 employees.
View email and phone details for 4
employees at Phalconbio.
Phalconbio's industry is
Biotechnology Research
Phalconbio's top competitors are
Mineraccel, Llc,
Insphero,
Xiretsa,
Pace-Amr,
Mycobiologics Ltd,
Micreos,
Yquantum Llc,
Phagesuisse,
Kasvu Therapeutics,
Hypo-Stream Ltd.
Phalconbio's categories are Biotechnology Research
